Publication at Second Faculty of Medicine |
2008
Abstract
Therapies based on the incretins in the last few years, become an integral part of the spectrum of interventions which are intended for the treatment of type 2 diabetes type. Clinical experience with inkretinovým mimetic (exenatide) and DPP 4 inhibitor (sitagliptin) confirm the results of the studies.
They not only define the therapy was effective and safe, but also as a therapy that has some advantages, which surpasses currently used drug. It is especially minimal risk of hypoglycemia and neutral effect on body weight (sitagliptin), or even a reduction in body weight (Exenatide).